• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Stryker Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

    2/27/25 4:30:29 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care
    Get the next $SYK alert in real time by email
    8-K
    STRYKER CORP Employee) false 0000310764 0000310764 2025-02-25 2025-02-25 0000310764 us-gaap:CommonStockMember 2025-02-25 2025-02-25 0000310764 syk:SeniorUnsecuredNotes2.125Due2027Member 2025-02-25 2025-02-25 0000310764 syk:SeniorUnsecuredNotes3.375Due2028Member 2025-02-25 2025-02-25 0000310764 syk:SeniorUnsecuredNotes0.750Due2029Member 2025-02-25 2025-02-25 0000310764 syk:SeniorUnsecuredNotes2.625Due2030Member 2025-02-25 2025-02-25 0000310764 syk:SeniorUnsecuredNotes1.000Due2031Member 2025-02-25 2025-02-25 0000310764 syk:SeniorUnsecuredNotes3.375Due2032Member 2025-02-25 2025-02-25 0000310764 syk:SeniorUnsecuredNotes3.625Due2036Member 2025-02-25 2025-02-25

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): February 25, 2025

     

     

     

    LOGO

    STRYKER CORPORATION

    (Exact name of registrant as specified in its charter)

     

    Michigan   001-13149   38-1239739
    (State of incorporation)   (Commission File Number)   (I.R.S. Employee Identification No.)
    1941 Stryker Way Portage, Michigan   49002
    (Address of principal executive offices)   (Zip Code)

    (269) 385-2600

    (Registrant’s telephone number, including area code)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, $.10 Par Value   SYK   New York Stock Exchange
    2.125% Notes due 2027   SYK27   New York Stock Exchange
    3.375% Notes due 2028   SYK28   New York Stock Exchange
    0.750% Notes due 2029   SYK29   New York Stock Exchange
    2.625% Notes due 2030   SYK30   New York Stock Exchange
    1.000% Notes due 2031   SYK31   New York Stock Exchange
    3.375% Notes due 2032   SYK32   New York Stock Exchange
    3.625% Notes due 2036   SYK36   New York Stock Exchange

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging Growth Company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    ITEM 1.01

    ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT

    On February 25, 2025, Stryker Corporation, and certain of its subsidiaries as designated borrowers, entered into a revolving credit agreement with various lenders and issuing banks and Wells Fargo Bank, National Association, as administrative agent (the “Credit Agreement”), that replaces its previous revolving credit agreement, dated as of October 26, 2021 (the “2021 Credit Agreement”). The principal terms of the Credit Agreement are: (1) an aggregate principal amount of commitments of $3.0 billion, (2) a maturity date of February 25, 2030 and (3) a leverage ratio financial covenant that provides for a maximum permitted leverage ratio of 3.75:1 at the end of any fiscal quarter, with an acquisition holiday no more than twice during the term of the Credit Agreement that permits the Company to elect to increase the maximum permitted leverage ratio by 1.0 to 4.75:1 for a period of four consecutive fiscal quarters, with the maximum permitted leverage ratio then stepping down by 0.25:1 for each of the next four quarters until it reaches 3.75:1, in connection with the consummation of certain material acquisitions. The Credit Agreement has an annual facility fee with respect to undrawn loans ranging from 7.0 to 15.0 basis points and loans under the Credit Agreement bear interest at either a Eurocurrency Rate, Term SOFR, Term CORRA Reference Rate or Base Rate (in each case as defined in the Credit Agreement), plus an applicable margin ranging from 0 to 10 basis points for Base Rate loans and 68 to 110 basis points for Eurocurrency Rate and RFR (as defined in the Credit Agreement) loans. The applicable margin for Eurocurrency Rate and RFR loans also applies to letters of credit. Both the facility fee and the applicable margin are dependent on the Company’s credit ratings. The representations and warranties, covenants and events of default contained in the Credit Agreement are substantially the same as those contained in the 2021 Credit Agreement. The foregoing summary is qualified in its entirety by the terms of the Credit Agreement, a copy of which is filed as Exhibit 10.1 hereto and is incorporated herein by reference.

     

    ITEM 2.03

    CREATION OF A DIRECT FINANCIAL OBLIGATION OR AN OBLIGATION UNDER AN OFF-BALANCE SHEET ARRANGEMENT OF A REGISTRANT

    The information set forth in Item 1.01 above with respect to the Credit Agreement is hereby incorporated by reference into this Item 2.03, insofar as it relates to the creation of a direct financial obligation.

     

    ITEM 9.01

    FINANCIAL STATEMENTS AND EXHIBITS

    (d) Exhibits

     

    10.1    Credit Agreement, dated as of February 25, 2025, among Stryker Corporation, certain of its subsidiaries as designated borrowers, the various lenders and issuing banks party thereto, and Wells Fargo Bank, National Association, as administrative agent
    104    Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

          STRYKER CORPORATION
          (Registrant)
    Date: February 27, 2025      

    /s/ GLENN S. BOEHNLEIN

          Glenn S. Boehnlein
          Vice President, Chief Financial Officer
    Get the next $SYK alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $SYK

    DatePrice TargetRatingAnalyst
    2/26/2025$450.00Buy
    Citigroup
    12/2/2024$370.00 → $445.00Equal-Weight → Overweight
    Morgan Stanley
    9/10/2024$405.00Outperform
    Wolfe Research
    5/30/2024$372.00Neutral
    Goldman
    5/22/2024$392.00Hold → Buy
    Needham
    1/31/2024$315.00 → $360.00Hold → Buy
    Canaccord Genuity
    10/20/2023$345.00Buy
    ROTH MKM
    9/5/2023$310.00 → $315.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $SYK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Stryker to announce financial results for its second quarter of fiscal year 2025

      Portage, Michigan, July 01, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for its second quarter of fiscal year 2025 on Thursday, July 31, 2025.  A press release will be issued at approximately 4:05 p.m. ET and available at Stryker - Press Releases that day. The press release will include summary financial information for the company's second quarter that ended June 30, 2025. Stryker will host a webcast at 4:30 p.m. ET on Thursday, July 31, 2025, to discuss its second quarter 2025 results.  The webcast can be accessed at Stryker - Events & Presentations.  An archive of the webcast will also be available on the company's website two hours after

      7/1/25 8:00:00 AM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • Stryker receives FDA clearance for Incompass Total Ankle System

      Streamlining total ankle replacement with data-driven implants and surgical flexibility Stryker (NYSE:SYK), a global leader in medical technologies, announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Incompass® Total Ankle System, an implant intended for patients with ankle joints damaged by severe rheumatoid, post-traumatic, or degenerative arthritis. This new platform integrates the innovative technologies of Stryker's Inbone® and Infinity® systems into a single, comprehensive solution for total ankle replacement. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250625296275/en/Stryker's

      6/25/25 8:15:00 AM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • Stryker receives FDA clearance for OptaBlate® BVN Basivertebral Nerve Ablation System

      Stryker's first basivertebral nerve ablation system targets the basivertebral nerve to provide relief from chronic* vertebrogenic low back pain. PORTAGE, Mich., May 19, 2025 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, announced that its OptaBlate basivertebral nerve ablation system (OptaBlate BVN) received 510(k) clearance from the U.S. Food and Drug Administration. OptaBlate BVNA is used in a targeted minimally invasive procedure providing long-lasting† vertebrogenic pain relief1. The addition of the OptaBlate BVN to Stryker's pain portfolio expands its advanced pain therapy solutions for patients and is an intersection of its two core competencies: radiofre

      5/19/25 1:01:00 PM ET
      $SYK
      Medical/Dental Instruments
      Health Care

    $SYK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citigroup resumed coverage on Stryker with a new price target

      Citigroup resumed coverage of Stryker with a rating of Buy and set a new price target of $450.00

      2/26/25 7:17:53 AM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • Stryker upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Stryker from Equal-Weight to Overweight and set a new price target of $445.00 from $370.00 previously

      12/2/24 7:02:55 AM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • Wolfe Research initiated coverage on Stryker with a new price target

      Wolfe Research initiated coverage of Stryker with a rating of Outperform and set a new price target of $405.00

      9/10/24 8:01:33 AM ET
      $SYK
      Medical/Dental Instruments
      Health Care

    $SYK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider King Debra

      3 - STRYKER CORP (0000310764) (Issuer)

      6/4/25 4:42:25 PM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • Amendment: VP, Chief Accounting Officer Berry William E Jr covered exercise/tax liability with 1,005 shares, decreasing direct ownership by 28% to 2,643 units (SEC Form 4)

      4/A - STRYKER CORP (0000310764) (Issuer)

      5/23/25 7:43:32 PM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • Amendment: VP, Chief Accounting Officer Berry William E Jr sold $211,370 worth of shares (755 units at $279.96), decreasing direct ownership by 29% to 1,853 units (SEC Form 4)

      4/A - STRYKER CORP (0000310764) (Issuer)

      5/23/25 7:39:38 PM ET
      $SYK
      Medical/Dental Instruments
      Health Care

    $SYK
    SEC Filings

    See more
    • SEC Form S-8 filed by Stryker Corporation

      S-8 - STRYKER CORP (0000310764) (Filer)

      5/30/25 4:16:27 PM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by Stryker Corporation

      SD - STRYKER CORP (0000310764) (Filer)

      5/23/25 10:35:54 AM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • Stryker Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - STRYKER CORP (0000310764) (Filer)

      5/13/25 5:29:41 PM ET
      $SYK
      Medical/Dental Instruments
      Health Care

    $SYK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Stryker Corporation (Amendment)

      SC 13G/A - STRYKER CORP (0000310764) (Subject)

      2/12/24 10:18:54 AM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Stryker Corporation (Amendment)

      SC 13G/A - STRYKER CORP (0000310764) (Subject)

      2/14/23 12:37:55 PM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Stryker Corporation (Amendment)

      SC 13G/A - STRYKER CORP (0000310764) (Subject)

      2/10/23 9:18:16 AM ET
      $SYK
      Medical/Dental Instruments
      Health Care

    $SYK
    Leadership Updates

    Live Leadership Updates

    See more
    • Stryker showcases next generation of Mako SmartRobotics™ at AAOS 2025 Annual Meeting

      Latest technology offers more applications and innovation across more specialties MAHWAH, N.J., March 11, 2025 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, showcases the latest advancements in Mako SmartRobotics™ across hip, knee, spine and shoulder procedures at the American Academy of Orthopaedic Surgeons' (AAOS) 2025 Annual Meeting in San Diego. With over 1.5 million Mako procedures performed globally across 45 countries, Mako is a market-leading technology in orthopaedics. With the introduction of Mako Total Hip with Advanced Primary and Rev

      3/11/25 8:03:00 AM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • Kadant Set to Join S&P SmallCap 600

      NEW YORK, Feb. 13, 2025 /PRNewswire/ -- Kadant Inc. (NYSE:KAI) will replace Inari Medical Inc. (NASD: NARI) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, February 19. S&P 500 constituent Stryker Corp. (NYSE:SYK) is acquiring Inari Medical in a deal expected to be completed soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name      Action Company Name Ticker GICS Sector February 19, 2025 S&P SmallCap 600 Addition Kadant KAI Industrials February 19, 2025 S&P SmallCap 600 Deletion Inari Medical NARI Health Care For more information about

      2/13/25 5:54:00 PM ET
      $KAI
      $NARI
      $SPGI
      $SYK
      Industrial Machinery/Components
      Industrials
      Medical/Dental Instruments
      Health Care
    • Stryker announces the retirement of Glenn S. Boehnlein and the promotion of Preston Wells to Vice President, Chief Financial Officer

      Portage, Michigan, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced today that Glenn S. Boehnlein will retire from his role as Vice President, Chief Financial Officer. Boehnlein's decision follows an impressive 22-year career at Stryker. Preston Wells, who currently serves as Group CFO for Stryker's Orthopaedics Group, will assume the role of Vice President, Chief Financial Officer effective April 1, 2025. "I want to thank Glenn for his performance drive, strong business partnership, and excellent leadership of the Finance and IT organizations. Glenn is a growth champion who invested in developing talent, including Preston Wells, who has been promoted to Chief Financial Offi

      1/28/25 4:05:00 PM ET
      $SYK
      Medical/Dental Instruments
      Health Care

    $SYK
    Financials

    Live finance-specific insights

    See more
    • Stryker declares an $0.84 per share quarterly dividend

      Portage, Michigan, May 08, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.84 per share payable July 31, 2025, to shareholders of record at the close of business on June 30, 2025, representing an increase of 5.0% versus the prior year and unchanged from the previous quarter.  About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150

      5/8/25 8:00:00 AM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • Stryker reports first quarter 2025 operating results

      Portage, Michigan, May 01, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the first quarter of 2025: First Quarter Results Reported net sales increased 11.9% to $5.9 billionOrganic net sales increased 10.1%Reported operating income margin of 14.3%Adjusted operating income margin(1) increased 100 bps to 22.9%Reported EPS decreased 17.6% to $1.69Adjusted EPS(1) increased 13.6% to $2.84  First Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures OrganicMedSurg and Neurotechnology        13.4        %         (0.8)        %         14.2        %         3.5        %         10.7        %Orthopaedics    

      5/1/25 4:05:00 PM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • Stryker completes acquisition of Inari Medical, Inc., providing entry into the high-growth peripheral vascular segment

      Portage, Michigan, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, announced today that it has completed the acquisition of Inari Medical, Inc. (NASDAQ:NARI), a company that provides innovative solutions for venous thromboembolism (VTE) clot removal without the use of thrombolytic drugs. The addition of Inari brings an established peripheral vascular position to Stryker in the fast-growing VTE segment. "The acquisition of Inari Medical marks a significant milestone in expanding our interventional endovascular portfolio," said Kevin Lobo, Chair and Chief Executive Officer, Stryker. "We look forward to welcoming the talented Inari team to Stryk

      2/19/25 8:30:00 AM ET
      $NARI
      $SYK
      Medical/Dental Instruments
      Health Care